Diltiazem controlled release formulation and method of manufacture
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/26
A61K-031/554
출원번호
US-0201747
(2005-08-11)
등록번호
US-8778395
(2014-07-15)
발명자
/ 주소
Cheng, Xiu Xiu
Qi, Xiaohong
Zhang, Guohua
Dixit, Manesh
출원인 / 주소
Andrx Labs, LLC
대리인 / 주소
Florek & Endres PLLC
인용정보
피인용 횟수 :
0인용 특허 :
84
초록
A controlled release diltiazem dosage formulation comprising a plurality of diltiazem pellets and a gel-forming material where the time of maximum diltiazem blood plasma levels occurs more than 8 hours after administration and preferably more than 10 hours after administration.
대표청구항▼
1. A controlled release oral pharmaceutical formulation comprising a tablet consisting of a mixture of (A) extended release diltiazem pellets, and (B) a gel-forming material, wherein (A) consists of: 45-75% of the total weight of the tablet and is a heterogeneous population of extended release dilti
1. A controlled release oral pharmaceutical formulation comprising a tablet consisting of a mixture of (A) extended release diltiazem pellets, and (B) a gel-forming material, wherein (A) consists of: 45-75% of the total weight of the tablet and is a heterogeneous population of extended release diltiazem pellets wherein the extended release diltiazem pellets comprise: i) a pellet core comprising diltiazem; andii) an extended release coating applied to the pellet core wherein the extended release coating controls the release of the drug from the pellet core so that the heterogeneous population of pellets exhibits a dissolution profile when tested in a USP Type 2 apparatus at 75 rpms, and 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) at 37° C.: 0-30% of the diltiazem is released after 2 hours;10-50% of the diltiazem is released after 4 hours;30-85% of the diltiazem is released after 8 hours;45-90% of the diltiazem is released after 12 hours;not less than 60% of the diltiazem is released after 16 hours;and not less than 70% of the diltiazem released after 20 hours;and (B) consists of: (i) a polymer that can retain a fraction of imbibed fluid and exhibit a 2 to 50 fold volume increase selected from the group consisting of polyhydroxyalkylcellulose having a molecular weight greater than 50,000, poly(hydroxyalkylmethacrylate) having a molecular weight of from 5,000 to 5,0000,000, an acrylic acid polymer, a polymer of acrylic acid cross-linked with a polyalkyl ether of sucrose, and polyethylene oxide having a molecular weight of 100,000 to 5,000,000; and(ii) conventional processing excipients selected from fillers, lubricants, glidants, pigments, polishing agents and combinations of the foregoing;wherein the mixture of (A) and (B) is compressed into a tablet and the combination of the extended release coating on the extended release pellets and the polymer of the gel-forming material controls the release of the diltiazem from the tablet so the time of maximum blood plasma diltiazem concentration occurs about 10 to about 15 hours after administration of the tablet;and wherein the tablet exhibits a dissolution profile when tested in a USP Type 1 apparatus at 100 rpms, and 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) at 37° C.: 0-30% of the diltiazem is released after 1 hour;0-40% of the diltiazem is released after 4 hours;not less than 30% of the diltiazem is released after 12 hours; andnot less than 60% of the diltiazem is released after 24 hours;and wherein the polymer of the gel-forming material is 5-25% of the total weight of the tablet and the gel-forming material is free of flux enhancers selected from the group consisting of magnesium sulfate, magnesium chloride, sodium chloride, potassium chloride, lithium chloride, potassium sulfate, sodium carbonate, sodium sulfate, lithium sulfate, potassium acid phosphate, calcium lactate, tartaric acid, lactose, fructose, sucrose, mannitol, sorbitol and mixtures thereof and the tablet may optionally be coated with a water soluble seal coat, aesthetic coat, color coat or polishing coat. 2. The formulation as defined in claim 1 wherein the time of maximum blood plasma diltiazem concentration occurs between 10 and 13 hours after administration of the formulation. 3. The formulation of claim 1 wherein the heterogeneous population of extended release pellets prior to mixing with the gel-forming material exhibits the following dissolution profile when tested in a USP Type 2 apparatus at 75 rpms, and 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) at 37° C.: 5-25% of the diltiazem is released after 2 hours;15-45% of the diltiazem is released after 4 hours;45-80% of the diltiazem is released after 8 hours;60-85% of the diltiazem is released after 12 hours;not less than 70% of the diltiazem is released after 16 hours; andnot less than 75% of the diltiazem released after 20 hours; and the tablet exhibits the following dissolution profile tested in a USP Type 1 apparatus at 100 rpms, and 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) at 37° C.: 0-20% of the diltiazem is released after 1 hour;0-30% of the diltiazem is released after 4 hours;not less than 40% of the diltiazem is released after 12 hours; andnot less than 70% of the diltiazem is released after 24 hours. 4. The formulation as described in claim 1 wherein the polymer of the gel-forming material is polyethylene oxide. 5. A controlled release oral pharmaceutical formulation comprising a tablet consisting of a mixture of (A) extended release diltiazem pellets, (B) polyethylene oxide, and (C) conventional processing excipients, wherein (A) consists of:45-75% of the total weight of the tablet of a heterogeneous population of extended release diltiazem pellets wherein the extended release diltiazem pellets comprise: i) a core comprising diltiazem and ii) an extended release coating applied to the core wherein the extended release coating controls the release of the diltiazem from the core so that the heterogeneous population of pellets exhibits the following dissolution profile when tested in a USP Type 2 apparatus at 75 rpms, and 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) at 37° C.: 0-30% of the diltiazem is released after 2 hours;10-50% of the diltiazem is released after 4 hours;30-85% of the diltiazem is released after 8 hours;45-90% of the diltiazem is released after 12 hours;not less than 60% of the diltiazem is released after 16 hours; andnot less than 70% of the diltiazem released after 20 hours;(B) consists of:5-25% of the total weight of the tablet of a polyethylene oxide having a molecular weight of 100,000 to 5,000,000;and (C) consists of: conventional processing excipients selected from fillers, lubricants, glidants, pigments, polishing agents and combinations of the foregoing wherein the mixture of (A), (B) and (C) is compressed into a tablet, and the combination of the extended release coating on the extended release pellets and polyethylene oxide controls the release of the diltiazem from the tablet so the time of maximum blood plasma diltiazem concentration occurs about 10 to about 15 hours after administration of the tablet, the tablet exhibits the following dissolution profile when tested in a USP Type 1 apparatus at 100 rpms, and 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) at 37° C.: 0-30% of the diltiazem is released after 1 hour;0-40% of the diltiazem is released after 4 hours;not less than 30% of the diltiazem is released after 12 hours; andnot less than 60% of the diltiazem is released after 24 hours; and wherein the polyethylene oxide is 1-40% of the total weight of the tablet and the polyethylene oxide and conventional processing excipients mixed with the extended release diltiazem pellets is free of flux enhancers selected from the group consisting of magnesium sulfate, magnesium chloride, sodium chloride, potassium chloride, lithium chloride, potassium sulfate, sodium carbonate, sodium sulfate, lithium sulfate, potassium acid phosphate, calcium lactate, tartaric acid, lactose, fructose, sucrose, mannitol, sorbitol and mixtures thereof and the tablet may optionally be coated with a water soluble seal coat, aesthetic coat, color coat or polishing coat.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (84)
Hunter William L.,CAX ; Machan Lindsay S.,CAX ; Arsenault A. Larry,CAX, Anti-angiogenic compositions and methods of use.
Geoghegan Edward J. (Athlone IEX) Mulligan Seamus (Athlone IEX) Panoz Donald E. (Tuckerstown BNX), Controlled absorption diltiazem formulation for once daily administration.
Geoghegan Edward J. (Athlone IEX) Mulligan Seamus (Athlone IEX) Panoz Donald E. (Tuckerstown BMX), Controlled absorption diltiazem formulation for once-daily administration.
Wong Patrick S. L. (Palo Alto CA) Barclay Brian L. (Sunnyvale CA) Deters Joseph C. (Los Altos CA) Theeuwes Felix (Los Altos CA), Controlled-release system with constant pushing source.
Soon-Shiong Patrick (Los Angeles CA) Desai Neil P. (Los Angeles CA) Heintz Roswitha E. (Los Angeles CA), Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials.
Hendrickson Dennis L. (Overland Park KS) Dimmitt Dan C. (Belton MO) Williams Mark S. (Kansas City MO) Skultety Paul F. (Leawood KS) Baltezor Michael J. (Lees Summit MO), Diltiazem formulation.
Hendrickson Dennis L. (Overland Park KS) Dimmitt Dan C. (Belton MO) Williams Mark S. (Kansas City MO) Skultety Paul F. (Leawood KS) Baltezor Michael J. (Lees Summit MO), Diltiazem formulation.
Hendrickson Dennis L. (Overland Park KS) Dimmitt Dan C. (Belton MO) Williams Mark S. (Kansas City MO) Skultety Paul F. (Leawood KS) Baltezor Michael J. (Lees Summit MO), Diltiazem formulation.
Theeuwes Felix (1643 Fallen Leaf La. Los Altos CA 94022) Wong Patrick S.-L. (1371 Xavier Ave. Hayward CA 94545) Cortese Richard (20802 Laurel Rd. Los Gatos CA 95030) Eckenhoff James B. (1080 Autumn L, Dispenser comprising displaceable matrix with solid state properties.
Wong Patrick S. L. (Hayward CA) Theeuwes Felix (Los Altos CA) Cortese Richard (Los Gatos CA) Eckenhoff James B. (Los Altos CA), Dispenser with movable matrix comprising a plurality of tiny pills.
Wong Patrick S.-L. (Hayward CA) Theeuwes Felix (Los Altos CA) Cortese Richard (Los Gatos CA) Eckenhoff James B. (Los Altos CA), Dispenser with movable matrix comprising a plurality of tiny pills.
Wong Patrick S. (Palo Alto CA) Theeuwes Felix (Los Altos CA) Ayer Atul D. (Palo Alto CA) Kuczynski Anthony L. (Palo Alto CA), Dosage form for time-varying patterns of drug delivery.
Wong Patrick S. (Palo Alto CA) Theeuwes Felix (Los Altos CA) Ayer Atul D. (Palo Alto CA) Kuczynski Anthony L. (Palo Alto CA), Dosage form for time-varying patterns of drug delivery.
David B. Masters, Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices.
Sawada, Toyohiro; Sako, Kazuhiro; Yoshioka, Tatsunobu; Watanabe, Shunsuke, Drug delivery system for averting pharmacokinetic drug interaction and method thereof.
Shell John W. ; Louie-Helm Jenny, Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter.
Theeuwes Felix (Los Altos CA) Wong Patrick S. L. (Hayward CA) Cortese Richard (Los Altos CA) Eckenhoff James B. (Los Altos CA), Juxtaposed laminated arrangement.
Desmolin Henri (Merignac FRX), Microbeads of diltiazem, a process for their manufacture and a substained-release pharmaceutical composition containing.
Canal Tiziana (Trieste ITX) Lovrecich Mara Lucia (Trieste ITX) Carli Fabio (Trieste ITX), Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active sub.
Klokkers-Bethke Karin (Monheim/Rhld. DEX) Fischer Wilfried (Burscheid DEX), Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manu.
Dong Liang C. (Mountain View CA) Dealey Michael H. (San Francisco CA) Burkoth Terry L. (Palo Alto CA) Wong Patrick S. L. (Palo Alto CA) Childers Jerry D. (Sunnyvale CA) Barclay Brian L. (Sunnyvale CA, Process for lessening irritation caused by drug.
Wong Patrick S. L. ; Dong Liang-Chang ; Edgren David E. ; Theeuwes Felix ; Gardner Phyllis I. ; Jao Francisco ; Wan Jason J., Prolonged release active agent dosage form adapted for gastric retention.
Wong, Patrick S.-L.; Dong, Liang-Chang; Edgren, David E.; Theeuwes, Felix; Gardner, Phyllis I.; Jao, Francisco; Wan, Jason J., Prolonged release active agent dosage form adapted for gastric retention.
Coutel Anne (Antony FRX) Lebreton Guy (Gif sur Yvette FRX) Veillard Michel (Sceaux FRX), Solid and porous single dosage form comprising particles in the form of beads and its preparation.
Stella Valentino J. ; Rajewski Roger A. ; Rao Venkatramana M. ; McGinity James W. ; Mosher Gerold L., Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations.
Jao Frank (San Jose CA) Wong Patrick S. L. (Palo Alto CA) Huynh Hoa T. (Fremont CA) McChesney Kathy (Cupertino CA) Wat Pamela K. (Santa Clara CA), Therapy delayed.
Jao Frank (San Jose) Wong Patrick S. L. (Palo Alto) Huynh Hoa T. (Fremont) McChesney Kathy (Cupertino) Wat Pamela K. (Santa Clara CA), Therapy delayed.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.